B7-33 represents a revolutionary advancement in peptide science—a single-chain relaxin mimetic that captures the powerful therapeutic potential of native H2 relaxin without its structural complexity . Unlike traditional two-chain relaxin peptides, this 27-amino acid linear peptide offers researchers a more practical, cost-effective alternative for investigating anti-fibrotic and cardioprotective mechanisms .
The science behind B7-33 is elegant yet profound. Natural H2 relaxin requires a complex two-chain, three-disulfide bond structure that makes synthesis difficult and expensive. B7-33 simplifies this architecture while retaining the RXFP1 receptor activation that drives its therapeutic effects . By preferentially activating the pERK signaling pathway over the cAMP pathway, B7-33 delivers targeted anti-fibrotic action with potentially fewer off-target concerns .
Molecular Formula: C₁₃₁H₂₂₈N₄₀O₃₇S
Molecular Weight: 2987.75 g/mol
Purity Available: Up to 99% HPLC grade
Cardiovascular Protection: Reducing Fibrosis and Inflammation
B7-33 demonstrates remarkable cardioprotective properties that distinguish it from conventional cardiovascular agents. In head-to-head comparisons against the ACE inhibitor perindopril, B7-33 showed superior anti-fibrotic effects while more rapidly reducing left ventricular fibrosis .
Key cardiovascular benefits observed in research models include:
- Reduced left ventricular inflammation – B7-33 normalizes inflammation markers linked to cardiomyopathy
- Decreased cardiomyocyte hypertrophy – Helps maintain healthy heart muscle cell size
- Restored blood vessel density – Supports proper vascularization and tissue perfusion
- Improved aortic contractility – Enhances vascular function
What makes B7-33 particularly compelling is its rapid-onset action. Unlike traditional treatments that may take weeks to show anti-fibrotic effects, B7-33 begins working quickly to address pathological tissue remodeling . For researchers studying heart failure, cardiomyopathy, or vascular dysfunction, this peptide offers a novel tool for investigating organ-protective mechanisms that operate independently of disease etiology .
Pregnancy-Related Research: Preeclampsia Applications
B7-33 shows significant promise for preeclampsia research—a serious hypertensive pregnancy disorder affecting approximately 10% of pregnancies worldwide . Current treatment options remain limited, making B7-33 an exciting candidate for understanding and potentially addressing this condition.
In rodent models of preeclampsia, B7-33 demonstrated the ability to:
- Normalize blood pressure in hypertensive models
- Reduce proteinuria, a key marker of kidney dysfunction
- Lower inflammatory markers including TNF-alpha
- Decrease sFlt-1 levels (soluble fms-like tyrosine kinase-1)
These effects were observed in both the RUPP (Reduction of Uterine Perfusion Pressure) model and the DOCA-salt model of preeclampsia, providing robust evidence of B7-33’s efficacy across different experimental approaches . For researchers investigating hypertensive disorders of pregnancy, maternal-fetal medicine, or reproductive immunology, B7-33 represents a novel research tool with demonstrated efficacy in preclinical models.
The peptide’s mechanism involves activation of the RXFP1 receptor—the same receptor targeted by native relaxin—suggesting it may replicate the beneficial vascular and anti-inflammatory effects of the endogenous hormone during pregnancy .
Anti-Fibrotic Mechanisms: Beyond Cardiovascular Applications
Fibrosis is a pathological feature of most chronic inflammatory diseases, contributing to organ dysfunction and failure through excessive extracellular matrix accumulation . Current anti-fibrotic therapies only delay disease progression and often carry significant side effects, creating urgent need for better research tools.
B7-33’s anti-fibrotic mechanism operates through selective activation of RXFP1-angiotensin II type 2 receptor heterodimers, triggering downstream signaling of pERK1/2 and the collagen-degrading enzyme matrix metalloproteinase-2 (MMP-2) . This targeted pathway activation may explain why B7-33 achieves potent anti-fibrotic effects with potentially fewer side effects than broader-acting agents.
Preclinical studies have demonstrated B7-33’s efficacy in multiple organ systems:
- Heart: Reduces cardiac fibrosis and hypertrophy
- Lungs: Shows promise in pulmonary fibrosis models
- Kidneys: Addresses fibrotic changes associated with hypertension
Importantly, B7-33 did not promote prostate tumor growth in vivo—a significant safety consideration, as native relaxin’s strong cAMP activation has been linked to tumor-promoting effects . This functional selectivity makes B7-33 particularly valuable for researchers investigating long-term anti-fibrotic strategies where safety profiles are paramount.
Technical Specifications and Research Applications
For laboratory research applications, B7-33 offers several practical advantages over native relaxin peptides:
Synthesis and Handling:
- Single-chain structure enables simpler, more cost-effective synthesis
- Improved stability compared to two-chain relaxin
- Available in various quantities (mg to kg scales)
Storage Requirements:
- -20°C lyophilized storage recommended
- Protect from light exposure
- Vacuum-packed for extended stability
Quality Specifications (Research Grade):
- HPLC Purity: ≥98-99%
- Appearance: White powder/lyophilized solid
- Endotoxin: ≤50 EU/mg
- Peptide Content: ≥80%
Primary Research Applications:
- Cardiovascular research – Heart failure, cardiomyopathy, hypertension
- Fibrosis studies – Organ fibrosis, wound healing, tissue remodeling
- Pregnancy research – Preeclampsia, gestational hypertension
- Vascular biology – Endothelial function, vessel density, contractility
Sequence: H-Val-Ile-Lys-Leu-Ser-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Ser-Gly-Met-Ser-Thr-Trp-Ser-Lys-Arg-Ser-Leu-OH
Why B7-33 Stands Out: Advantages Over Native Relaxin
B7-33 solves key limitations of native H2 relaxin that have historically challenged researchers:
1. Simplified Structure
Native H2 relaxin requires complex two-chain, three-disulfide bond synthesis. B7-33’s single-chain linear design dramatically reduces production complexity and cost while maintaining therapeutic efficacy .
2. Functional Selectivity
Unlike native relaxin which strongly activates cAMP signaling (potentially linked to tumor promotion), B7-33 preferentially activates the pERK pathway associated with anti-fibrotic effects .
3. Equivalent Efficacy at Lower Doses
Research shows B7-33 (0.25 mg/kg/day) achieves equivalent cardioprotective effects to native relaxin (0.5 mg/kg/day)—half the dose for the same benefit .
4. Better Safety Profile
B7-33 did not exacerbate prostate tumor growth in animal models—an important consideration for long-term therapeutic research .
5. More Rapid Onset
In comparative studies, B7-33 demonstrated faster anti-fibrotic effects than both native relaxin and ACE inhibitors .
Important Research Use Disclaimer
FOR RESEARCH USE ONLY
B7-33 peptide is supplied exclusively for laboratory research and scientific investigation purposes. This product is:
- Not for human consumption (in vitro or in vivo human use)
- Not for therapeutic or diagnostic applications
- Not for veterinary use
The information provided regarding B7-33’s biological activities, mechanisms, and potential applications is derived from published peer-reviewed literature and is intended solely to inform research directions. Researchers assume full responsibility for compliance with all applicable institutional, local, and national regulations governing peptide research
